Recently, the use of GLP-1 receptor agonists (liraglutide and semaglutide) following recurrent weight gain has shown results in weight loss very similar to those observed when these drugs are used as primary obesity treatments (73-75). This evidence concerns the gene GLP1R and Obesity.